Shares of Phibro Animal Health (PAHC) have been strong performers lately, with the stock up 25.9% over the past month. The stock hit a new 52-week high of $50.05 in the previous session. Phibro has gained 33.8% since the start of the year compared to the 3.1% gain for the Zacks Medical sector and the -3.6% return for the Zacks Medical - Products industry.
What's Driving the Outperformance?
The stock has a great record of positive earnings surprises, having beaten the Zacks Consensus Estimate in each of the last four quarters. In its last earnings report on February 4, 2026, Phibro reported EPS of $0.87 versus consensus estimate of $0.69.
For the current fiscal year, Phibro is expected to post earnings of $2.83 per share on $1.47 in revenues. This represents a 35.41% change in EPS on a 13.51% change in revenues. For the next fiscal year, the company is expected to earn $2.94 per share on $1.51 in revenues. This represents a year-over-year change of 3.98% and 2.35%, respectively.
Valuation Metrics
Phibro may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself.
On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). The individual style scores for Value, Growth, Momentum and the combined VGM Score run from A through F. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.
Phibro has a Value Score of B. The stock's Growth and Momentum Scores are B and B, respectively, giving the company a VGM Score of A.
In terms of its value breakdown, the stock currently trades at 17.7X current fiscal year EPS estimates, which is not in-line with the peer industry average of 19.4X. On a trailing cash flow basis, the stock currently trades at 15.3X versus its peer group's average of 9.3X. Additionally, the stock has a PEG ratio of 1.38. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks Rank
We also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. Fortunately, Phibro currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Phibro fits the bill. Thus, it seems as though Phibro shares could have potential in the weeks and months to come.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Phibro Animal Health Corporation (PAHC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
